Sentynl Therapeutics announces USFDA Acceptance and Priority Review of NDA for CUTX-101
Sentynl Therapeutics, Inc. a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd and Fortress Biotech, Inc. announced that the U.S. Food and Drug Administration has accepted for filing and Priority review Sentynls New Drug Application for CUTX-101